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 Major depressive disorder is highly prevalent among women with HIV and is 
associated with decreased antiretroviral therapy adherence and increased risk of 
mortality. As major depressive disorder often goes undiagnosed among women with 
HIV, one proposed solution to this problem has been to establish routine depression 
screening and integrated psychiatric care as part of HIV treatment. However, the high 
prevalence of other psychiatric and substance use disorders among women with HIV 
complicates the accurate diagnosis of major depressive disorder, as depressive 
symptoms are common across these distinct disorders with varying treatment 
recommendations. While previous studies have validated screening tools, such as the 
Beck Depression Inventory, for major depressive disorder among women with HIV, 
none have addressed the extent to which the presence of these other conditions results 
in psychiatric misdiagnosis.  
 This thesis addresses this gap by examining the impact of psychiatric disorders 
and substance use behaviors on the validity of the Beck Depression Inventory in 
screening for major depressive disorder among women with HIV. Women in our sample 
were engaged in care at the Johns Hopkins HIV Clinic and were recruited between April 
2006 and July 2010 to join a trial of a brief intervention for hazardous alcohol use. Using 
baseline trial data, we compare women’s Beck Depression Inventory scores to their 
major depressive disorder diagnosis obtained from a structured clinical interview and 
calculate sensitivity and specificity in the full study population and stratified by post-




 Beck Depression Inventory sensitivity and specificity were 65% and 75% overall. 
Sensitivity was higher among women with current (79%) or lifetime (74%) PTSD 
compared to those without a current (55%) or lifetime (53%) diagnosis. Sensitivity did 
not vary by alcohol use risk classification. Specificity was higher among women without 
current (78%) or lifetime (81%) PTSD, without BPAD (78%), or with low-risk alcohol use 
(80%), and lower among women with these diagnoses (59%, 66%, 62%) or with 
hazardous alcohol use (68%). We discuss the implications of these results for 
transdiagnostic psychiatry in HIV care and highlight the need for evaluating major 
depressive disorder in the context of other psychiatric and behavioral factors prevalent 
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Major depressive disorder (MDD) is the most common psychiatric comorbidity 
among people living with HIV (PLWH), with current prevalence estimates ranging from 
30% to 40%.1,2,3 Beyond its associations with decreased quality of life4 and behaviors 
carrying increased risk for HIV transmission, 5,6 MDD is also linked to decreased 
retention in routine HIV care,7,8 decreased antiretroviral therapy (ART) adherence,9,10 
increased viral load,11,12,13 and increased risk of mortality.14,15 Although several 
psychotherapeutic and pharmacologic interventions are effective in treating MDD 
among PLWH,16,17,18,19 it remains a highly prevalent, modifiable risk factor for poor HIV 
treatment outcomes. 
Substantial disparities in the prevalence of MDD and its association with worse 
HIV outcomes exist for women living with HIV (WLWH) compared to other populations. 
WLWH are nearly twice as likely to receive an MDD diagnosis as women in the general 
population20,21 and are more likely to report depressive symptoms and be indicated for 
MDD treatment than men living with HIV.22,23,24 Prospective studies have found that 
chronic MDD is associated with increased viral load and a nearly two-fold increase in 
the risk of death among WLWH in both the pre-ART and ART eras of HIV care.15,25 This 
increase in all-cause mortality is even more striking among WLWH with MDD who have 
not yet initiated ART.26 Identifying MDD among WLWH and connecting them to 
integrated behavioral and pharmacological care, both prior to and after initiation of ART, 




However, the extremely high prevalence of other psychiatric disorders and 
substance use behaviors among WLWH complicates the accurate diagnosis of MDD 
and the referral of patients to appropriate evidence-based care. The prevalence of 
bipolar affective disorders,8,20 post-traumatic stress disorder (PTSD),20,27 substance use 
disorders,20 and hazardous alcohol use20,28 among WLWH each far exceed levels 
among women in the general population. Because symptoms of these conditions 
overlap with symptoms of MDD assessed using common screening tools, misdiagnosis 
of MDD can be common in populations with high prevalence of other psychiatric and 
substance use disorders.29,30 Thus, while MDD is often underdiagnosed among 
WLWH,31,32 another concern is that WLWH with depressive symptoms stemming from 
other disorders with unique treatment practices may be misdiagnosed with MDD when 
assessed using MDD-specific screening tools alone. Identifying groups of WLWH most 
likely to be underdiagnosed or overdiagnosed by these screening tools can have 
important downstream impacts on their HIV treatment outcomes. 
Several studies have investigated the validity of the Beck Depression Inventory-II 
(BDI-II) among PLWH, with sensitivities between 74% and 95% and specificities 
between 68% and 74%.33,34,35 While these findings align with estimates of BDI-II 
sensitivity and specificity in general population samples across several countries,36,37 
they do not address diagnostic accuracy among WLWH specifically. These studies also 
have substantial limitations, such as the use of another self-reported screening tool as a 
gold standard assessment for an MDD diagnosis, and none of these studies assess the 
extent to which the prevalence of other psychiatric conditions or substance use 
behaviors may lead to differential accuracy in screening for MDD.  
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Our study aims to address these gaps by examining psychiatric disorders and 
substance use behaviors that impact validity of the BDI-II in screening for MDD among 
WLWH. Using data from a study of WLWH engaged in HIV care in Baltimore, MD, we 
first examine whether the accuracy of the BDI-II among these women aligns with 
previous estimates obtained in general populations of PLWH. We then assess whether 
the accuracy of the BDI-II varies across women with PTSD, bipolar affective disorder, 
and hazardous alcohol use. Finally, we discuss the implications of these findings on the 
evaluation of MDD among WLWH in the context of comorbidity and the non-specificity 
of depressive symptoms in this population.   
 
2. Methods 
2.1 Study population 
 Women in our sample were recruited from the Johns Hopkins HIV Clinic. One 
group that consumed alcohol at heavy or hazardous levels were recruited as part of a 
randomized controlled trial of a brief intervention for hazardous drinking among WLWH. 
Study investigators used two concurrent recruitment approaches based on potential 
participants’ drinking behaviors, as assessed by the first three items (i.e., quantity and 
frequency) of the Alcohol Use Disorders Identification Test (AUDIT)38 and the full 
Tolerance, Worried, Eye-opener, Amnesia, Cut Down (TWEAK)39 test at screening. 
Women met criteria for heavy or hazardous alcohol use if they reported consuming 
eight or more alcoholic drinks per week, reported two or more binge drinking episodes 
(four or more drinks per occasion) in the prior six months, or had a score of two or 
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higher on the TWEAK. Women who met at least one of these criteria were then 
randomized to either the brief intervention or to the usual standard of care. A 
comparison group of low-risk or non-drinkers consisted of women who reported either 
no alcohol consumption or drinking behaviors that did not meet the study criteria for 
heavy or hazardous alcohol use. All women were 18 years of age or older and were 
receiving care in the Johns Hopkins HIV Clinic between April 2006 and July 2010. 
Women were deemed ineligible if they were experiencing an active psychotic episode, 
were pregnant, or were currently enrolled in a treatment program for alcohol use.  
Complete descriptions of the larger study design and protocol have been 
published previously.40,41,42 The Johns Hopkins University School of Medicine 
Institutional Review Board reviewed and approved both the intervention study and this 
secondary analysis. 
2.2 Data sources 
 Women completed the 21-item BDI-II43 using an audio computer-assisted self-
interview (ACASI) at the time of study enrollment. The BDI-II has empirically 
demonstrated high internal consistency and test-retest reliability and has been shown to 
capture both mood and somatic factors contributing to MDD.44,45  
 We obtained diagnoses of MDD, bipolar affective disorders, and PTSD from the 
non-patient version of the Structured Clinical Diagnostic Interview (SCID), a series of 
standardized modules considered a gold standard for the diagnosis of Axis-I psychiatric 
disorders outlined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV).46 Two trained master’s level therapists administered and scored the 
SCID within one month after study enrollment. Two research assistants then 
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independently reviewed diagnostic coding for accuracy, with lingering discrepancies 
adjudicated by two study investigators (HH and GC) to obtain a final diagnosis.   
 Women completed the first three items of the AUDIT and the 5-item TWEAK 
scale at study screening. The AUDIT has proven to be a highly reliable and valid 
assessment of hazardous alcohol use across a range of populations with varying 
comorbidities.47,48,49 The TWEAK was originally developed for use with pregnant 
women, but it has subsequently been shown to capture alcohol-related problems 
indicative of disordered use or dependence in the general population and in outpatient 
care facilities.50 Additionally, women provided information on past 90-day illicit drug use, 
including cocaine and heroin use, at study enrollment using a Timeline Followback 
(TLFB) interview.51 
2.3 Analytic approach 
 We first examined the validity of the BDI-II with respect to a SCID diagnosis of 
current MDD in the full sample, which includes all women regardless of PTSD or bipolar 
affective disorder diagnosis or alcohol use classification. Congruent with official scoring 
guidelines for the BDI-II,40 we summed item ratings to create a total scale score for each 
participant, which we dichotomized to define MDD at a cutoff score of ≥20 to indicate 
moderate or severe depressive symptoms. We then calculated sensitivity and specificity 
for the BDI-II using this criterion. 
 Second, we stratified participants based on the presence or absence of SCID 
diagnoses of current and lifetime PTSD and lifetime bipolar affective disorder and used 
the previously defined BDI-II cutoff criterion to calculate sensitivity and specificity of the 
BDI-II given these psychiatric conditions. As bipolar affective disorders are lifelong, 
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episodic conditions,52 we limited our analysis to lifetime diagnosis of bipolar affective 
disorder-I or bipolar affective disorder-II assessed via the SCID. Additionally, because 
DSM-IV guidelines preclude an MDD diagnosis if a depressive episode is determined to 
be the product of bipolar affective disorder,53 we did not calculate BDI-II sensitivity 
among women with a bipolar affective disorder diagnosis.  
 Finally, we stratified participants based on self-reported recent alcohol use and 
alcohol-related problems. Participants were classified as low-risk drinkers or hazardous 
drinkers based on the first three items of the AUDIT (≥8 drinks per week or ≥2 binge 
drinking episodes in the prior six months) and their total TWEAK score (≥2). We 
calculated sensitivity and specificity for the BDI-II conditional on these alcohol use 
criteria. 
 We completed all statistical analyses in Stata 16.54  
 
3. Results 
3.1 Participant Characteristics 
 Our study sample consisted of 372 WLWH who had complete BDI-II data at their 
baseline study visit and completed the SCID within one month of ACASI completion. 
Our sample excluded 13 women with missing baseline ACASI data and three women 
with missing SCID data. The median age was 46 years old (41, 52), and women 
identified predominantly as non-Hispanic Black (86%) and heterosexual (90%). Only 
10% of women were employed full-time (and only 7% employed part-time), explaining 
the median income of $7,968 ($5,160, $9,048). Reflecting a study population currently 
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engaged in HIV care, women had a median CD4 count of 433 cells/mm3 (268, 647), and 
most were on ART at the time of assessment (79%) and had HIV-1 RNA levels of fewer 
than 50 copies/mL (55%). Participant characteristics can be found in Table 3.1.  
 
Table 3.1. Participant characteristics 
Variable Study Sample (N = 372) 
Demographics  
  Age, years [median (Q1, Q3)] 46 (41, 52) 
  Education (#, %) 
     <12 years 




  Race (#, %) 
     Non-Hispanic Black 
     Non-Hispanic white 
     Hispanic 
     American Indian 







  Sexual orientation (#, %) 
     Heterosexual 
     Homosexual 
     Bisexual 






  Employment status (#, %) 
     Working full-time 
     Working part-time 
     Looking for work 






  Income, dollars [median, (Q1, Q3)] 7,968 (5,160, 9,048) 
HIV Characteristics  
  Undetectable HIV-1 RNA (<50 copies/mL) (#, %) 205 (55%) 
  CD4 count, cells/mm3 [median, (Q1, Q3)] 433 (268, 647) 
  On ART (#, %) 293 (79%) 
Substance Use  
  Classified as hazardous drinker (HD) in original study (#, %) 143 (38%) 
  Past 90-day cocaine use (#, %) 77 (20.7%) 




In the full sample, the SCID-based prevalence of current MDD was 9% (95% CI: 
6%, 13%). Approximately 13% of women in our sample had a SCID-confirmed lifetime 
diagnosis of bipolar affective disorder. PTSD was highly prevalent, with 36% of women 
having a lifetime diagnosis and 17% of women having a current diagnosis, and MDD-
PTSD comorbidity was common. The prevalence of MDD was 14% among women with 
a lifetime PTSD diagnosis (compared to 6% among women without a lifetime diagnosis) 
and 22% among women with a current PTSD diagnosis (compared to 7% among 
women without a current diagnosis). MDD prevalence among women classified as 
having high-risk drinking under the original study criteria was 12% (95% CI: 7%, 18%), 
whereas only 7% (95% CI: 4%, 12%) of women who reported low-risk drinking had an 
MDD diagnosis.  
3.2 Diagnostic Accuracy of the BDI-II  
 BDI-II test validity is presented in Table 3.2. Under the recommended scoring 
cutoff of 20, the BDI-II had a sensitivity of 65% (95% CI: 47%, 80%) and a specificity of 





















Overall (N = 372) 9% (6%, 13%) 65% (47%, 80%) 75% (71%, 80%) 
Lifetime PTSD (N = 371) 
   Positive diagnosis (N = 135) 
   No diagnosis (N = 236) 
 
14% (9%, 21%) 
6% (4%, 10%) 
 
74% (49%, 91%) 
53% (27%, 79%) 
 
66% (56%, 74%) 
81% (75%, 86%) 
Current PTSD (N = 372) 
   Positive diagnosis (N = 63) 
   No diagnosis (N = 309) 
 
22% (13%, 35%) 
7% (4%, 10%) 
 
79% (49%, 95%) 
55% (32%, 77%) 
 
59% (44%, 73%) 
78% (73%, 83%) 
Lifetime BPAD (N = 372) 
   Positive diagnosis (N = 47) 
   No diagnosis (N = 325) 
 
--- 
10% (7%, 14%) 
 
--- 
65% (46%, 80%) 
 
62% (46%, 75%) 
78% (72%, 82%) 
Alcohol use (N = 372) 
   Low-risk alcohol use (N = 229) 
   Hazardous alcohol use (N = 143) 
 
7% (4%, 12%) 
12% (7%, 18%) 
 
65% (38%, 86%) 
65% (38%, 86%) 
 
80% (74%, 85%) 
68% (59%, 86%) 
Note: BPAD = bipolar affective disorder. MDD prevalence and BDI-II sensitivity are not calculated, as DSM-IV 
guidelines preclude a major depressive disorder diagnosis given a diagnosis of bipolar affective disorder. 
  
 BDI-II accuracy varied based on both lifetime and current diagnoses of PTSD. 
BDI-II sensitivity and specificity were 74% (95% CI: 49%, 91%) and 66% (95% CI: 56%, 
74%), respectively, among women with a lifetime PTSD diagnosis compared to 53% 
(95% CI: 27%, 79%) and 81% (95% CI: 75%, 86%) among women without a lifetime 
diagnosis. When we stratified women by current PTSD diagnosis, BDI-II sensitivity was 
79% (95% CI: 49%, 95%) and specificity was 59% (95% CI: 44%, 73%) among women 
with a current diagnosis compared to 55% (95% CI: 32%, 77%) and 78% (95% CI: 73%, 
83%) among women without a current diagnosis.  
BDI-II specificity in people without bipolar affective disorder (78%, 95% CI: 72%, 
82%) was higher than that obtained using the full sample of all women. BDI-II specificity 
among those with a bipolar affective disorder diagnosis was only 62% (95% CI: 46%, 
75%), indicating that the BDI-II inaccurately classified 38% of women with bipolar 
affective disorder as having unipolar major depressive disorder. 
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 Finally, BDI-II sensitivity was 65% (95% CI: 38%, 86%) in both the HD and ND 
alcohol use groups, but specificity was higher among ND women (80%, 95% CI: 74%, 
85%) compared to HD women (68%, 95% CI: 59%, 86%).  
 
4. Discussion 
 In a sample of women engaged in HIV care in Baltimore, MD, we found that 
diagnostic accuracy of the BDI-II was influenced by the presence of comorbid 
psychiatric disorders and hazardous alcohol use.  Specifically, BDI-II sensitivity was 
higher among women with a lifetime or current diagnosis of PTSD, but it did not vary 
when stratified by alcohol use. Specificity was higher among women without a lifetime 
or current diagnosis of PTSD, without a bipolar affective disorder diagnosis, and low-risk 
alcohol use, and lower among women with these diagnoses or with hazardous alcohol 
use. 
Our findings highlight the importance of evaluating MDD among WLWH within 
the context of other psychiatric disorders that have overlapping symptom dimensions, 
particularly given the high degree of comorbidity in this population. For example, we 
found that PTSD increased the overall likelihood that women would screen positively for 
MDD on the BDI-II, resulting in a higher likelihood of both correctly classifying those with 
comorbid disorders and incorrectly classifying those with PTSD alone. One solution to 
this imprecision in symptom classification may involve balancing a lower BDI-II 
screening threshold with the removal of items with high overlap between MDD and 
PTSD, but such an approach may exacerbate the issue of assigning those with bipolar 
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affective disorders an improper diagnosis of MDD. The crossover of depressive 
symptoms between these prevalent disorders among WLWH should instead underscore 
the need for comprehensive psychiatric screening for MDD in HIV care settings rather 
than relying upon unidimensional screening measures in isolation. Adopting a 
transdiagnostic approach, which focuses on the common etiologic roots across 
psychiatric disorders and emphasizes flexible nosology over prescriptive categorical 
approaches,55 can improve the diagnosis and treatment of these conditions among 
WLWH by situating depressive symptoms within the broader psychiatric context of this 
population.   
The non-specificity of depressive symptoms among WLWH has key implications 
for adequate and relevant treatment of MDD. Mirroring the treatment cascade seen 
along the HIV care continuum,56,57 an estimated 45% of prevalent MDD cases among 
PLWH are recognized clinically, with only 40% of these recognized cases currently 
receiving treatment and less than one-third of these treated PLWH achieving 
remission.58 While these measures indicate a need for integration of routine MDD 
screening and referral to psychiatric care in HIV treatment settings, the extent to which 
this rapid decline along the care continuum may be attributable to diagnostic 
misclassification and improper treatment stemming from screen-then-treat approaches 
remains unclear. Several studies using screening-based criteria for MDD have 
demonstrated the effectiveness of antidepressant treatment in reducing depressive 
symptoms among PLWH, but high variation in these estimates could be explained by a 
lack of attention to psychiatric comorbidity or alternative diagnoses.59 For instance, 
people with comorbid MDD and PTSD may respond more poorly to antidepressant 
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treatment compared to those with MDD alone, a pattern also seen in trials involving 
cognitive behavioral therapies.60,61 Among people with BPAD, antidepressant treatment 
can trigger the exacerbation of depressive symptoms or the induction of rapid cycling 
between depressive and manic states.62,63 The disproportionately high rates of these 
disorders among WLWH64 therefore favor screen-then-interview approaches for MDD 
over screen-then-treat strategies that ignore the non-specificity of depressive symptoms 
in this population and may preclude referral to adequate MDD care or appropriate care 
for other diagnoses. 
 Our findings are consistent with previous studies showing that WLWH who 
report hazardous alcohol use are more likely than those reporting no or low-risk alcohol 
use to have MDD.65,66,67 However, women reporting hazardous alcohol use were also 
more likely to falsely screen positive for MDD on the BDI-II, which may explain why our 
prevalence estimate of this comorbidity using SCID-confirmed MDD diagnoses is lower 
than those found in these studies using screening tool criteria. Notably, using a 
structured clinical interview to identify MDD can exclude cases in which depressive 
symptoms are the product of alcohol withdrawal or acute intoxication, which lead to a 
separate categorical diagnosis of substance-induced mood disorder.68 This context 
provides further support for multidimensional behavioral health screening combined with 
clinical interviews that can inform appropriate combinations of pharmacologic and 
behavioral interventions to reduce both depressive symptoms and hazardous drinking 
among WLWH.  
Our study has two notable limitations. First, our study population was limited to 
WLWH engaged in HIV care who were able and willing to participate in a research study 
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including intensive questionnaires and interviews. As women with severe MDD may be 
more likely to abstain from study participation69 and less likely to be engaged in HIV 
treatment,7,8 selection into our study could be conditional upon having fewer or less 
severe depressive symptoms, potentially explaining why our prevalence estimate of 
current MDD is lower than other epidemiologic studies involving WLWH.20,21,22 However, 
this lower estimate is also likely related to our use of SCID-confirmed MDD diagnoses, 
which use more specific diagnostic criteria than screening tools and can rule out 
depressive symptoms attributable to PTSD, bipolar affective disorder, or alcohol use. 
Finally, illicit substance use disorders are highly prevalent among WLWH20 and may 
further complicate the screening-based diagnosis of MDD. In our sample, 21% of 
women reported cocaine use and 10% reported heroin use in the 90 days prior to their 
baseline study visit using the TLFB. With only these prevalence data, we were unable to 
reliably determine whether these women met criteria for an associated substance use 
disorder. Future studies should investigate the impact of drug use on MDD screening 
accuracy using assessment methods that account for both the quantity and frequency of 
drug use and the behavioral factors and consequences that characterize substance use 
disorders. 
Overall, our study highlights the issues in trading efficiency for accuracy when 
using screening-based approaches for identifying MDD among WLWH and provides 
empirical evidence for transdiagnostic psychiatry as part of routine HIV care. Diagnostic 
approaches informed by the non-specificity of depressive symptoms in this population 
are critical to ensuring referral to adequate psychiatric treatment and therefore 
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minimizing the detrimental impact of MDD, other psychiatric disorders, and substance 
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